Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Ntrk1 Promotes Resistance to PD-1 Checkpoint Blockade in Mesenchymal Kras/p53 Mutant Lung Cancer.

Konen JM, Rodriguez BL, Fradette JJ, Gibson L, Davis D, Minelli R, Peoples MD, Kovacs J, Carugo A, Bristow C, Heffernan T, Gibbons DL.

Cancers (Basel). 2019 Apr 2;11(4). pii: E462. doi: 10.3390/cancers11040462.

2.

A novel ex vivo tumor system identifies Src-mediated invasion and metastasis in mesenchymal tumor cells in non-small cell lung cancer.

Padhye A, Ungewiss C, Fradette JJ, Rodriguez BL, Albritton JL, Miller JS, Gibbons DL.

Sci Rep. 2019 Mar 20;9(1):4819. doi: 10.1038/s41598-019-41301-2.

3.

Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer.

Sen T, Rodriguez BL, Chen L, Corte CMD, Morikawa N, Fujimoto J, Cristea S, Nguyen T, Diao L, Li L, Fan Y, Yang Y, Wang J, Glisson BS, Wistuba II, Sage J, Heymach JV, Gibbons DL, Byers LA.

Cancer Discov. 2019 May;9(5):646-661. doi: 10.1158/2159-8290.CD-18-1020. Epub 2019 Feb 18.

PMID:
30777870
4.

CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade.

Chen L, Diao L, Yang Y, Yi X, Rodriguez BL, Li Y, Villalobos PA, Cascone T, Liu X, Tan L, Lorenzi PL, Huang A, Zhao Q, Peng D, Fradette JJ, Peng DH, Ungewiss C, Roybal J, Tong P, Oba J, Skoulidis F, Peng W, Carter BW, Gay CM, Fan Y, Class CA, Zhu J, Rodriguez-Canales J, Kawakami M, Byers LA, Woodman SE, Papadimitrakopoulou VA, Dmitrovsky E, Wang J, Ullrich SE, Wistuba II, Heymach JV, Qin FX, Gibbons DL.

Cancer Discov. 2018 Sep;8(9):1156-1175. doi: 10.1158/2159-8290.CD-17-1033. Epub 2018 Jul 16.

5.

Synthesis, Characterization, and In Vitro and In Vivo Evaluations of 4-(N)-Docosahexaenoyl 2', 2'-Difluorodeoxycytidine with Potent and Broad-Spectrum Antitumor Activity.

Naguib YW, Lansakara-P D, Lashinger LM, Rodriguez BL, Valdes S, Niu M, Aldayel AM, Peng L, Hursting SD, Cui Z.

Neoplasia. 2016 Jan;18(1):33-48. doi: 10.1016/j.neo.2015.11.012.

6.

Multiple isoforms of phosphoenolpyruvate carboxylase in the Orchidaceae (subtribe Oncidiinae): implications for the evolution of crassulacean acid metabolism.

Silvera K, Winter K, Rodriguez BL, Albion RL, Cushman JC.

J Exp Bot. 2014 Jul;65(13):3623-36. doi: 10.1093/jxb/eru234. Epub 2014 Jun 9.

7.

Solid lipid nanoparticle formulations of docetaxel prepared with high melting point triglycerides: in vitro and in vivo evaluation.

Naguib YW, Rodriguez BL, Li X, Hursting SD, Williams RO 3rd, Cui Z.

Mol Pharm. 2014 Apr 7;11(4):1239-49. doi: 10.1021/mp4006968. Epub 2014 Mar 12.

8.

Antitumor activity of tumor-targeted RNA replicase-based plasmid that expresses interleukin-2 in a murine melanoma model.

Rodriguez BL, Blando JM, Lansakara-P DS, Kiguchi Y, DiGiovanni J, Cui Z.

Mol Pharm. 2013 Jun 3;10(6):2404-15. doi: 10.1021/mp400033m. Epub 2013 May 17.

9.

Molecular targeting of liposomal nanoparticles to tumor microenvironment.

Zhao G, Rodriguez BL.

Int J Nanomedicine. 2013;8:61-71. doi: 10.2147/IJN.S37859. Epub 2012 Dec 28. Review.

10.

Synthesis and in vitro evaluation of novel lipophilic monophosphorylated gemcitabine derivatives and their nanoparticles.

Lansakara-P DS, Rodriguez BL, Cui Z.

Int J Pharm. 2012 Jun 15;429(1-2):123-34. doi: 10.1016/j.ijpharm.2012.03.014. Epub 2012 Mar 16. Erratum in: Int J Pharm. 2012 Nov 15;438(1-2):336.

11.

Control of solid tumor growth in mice using EGF receptor-targeted RNA replicase-based plasmid DNA.

Rodriguez BL, Li X, Kiguchi K, DiGiovanni J, Unger EC, Cui Z.

Nanomedicine (Lond). 2012 Apr;7(4):475-91. doi: 10.2217/nnm.11.112. Epub 2012 Feb 2.

12.

EGFR-targeted stearoyl gemcitabine nanoparticles show enhanced anti-tumor activity.

Sandoval MA, Sloat BR, Lansakara-P DS, Kumar A, Rodriguez BL, Kiguchi K, Digiovanni J, Cui Z.

J Control Release. 2012 Jan 30;157(2):287-96. doi: 10.1016/j.jconrel.2011.08.015. Epub 2011 Aug 17.

13.

Permeation of antigen protein-conjugated nanoparticles and live bacteria through microneedle-treated mouse skin.

Kumar A, Li X, Sandoval MA, Rodriguez BL, Sloat BR, Cui Z.

Int J Nanomedicine. 2011;6:1253-64. doi: 10.2147/IJN.S20413. Epub 2011 Jun 21.

14.

Replicase-based plasmid DNA shows anti-tumor activity.

Rodriguez BL, Yu Z, Chung WG, Weiss R, Cui Z.

BMC Cancer. 2011 Mar 28;11:110. doi: 10.1186/1471-2407-11-110.

15.

The extent of the uptake of plasmid into the skin determines the immune responses induced by a DNA vaccine applied topically onto the skin.

Yu Z, Chung WG, Sloat BR, Löhr CV, Weiss R, Rodriguez BL, Li X, Cui Z.

J Pharm Pharmacol. 2011 Feb;63(2):199-205. doi: 10.1111/j.2042-7158.2010.01219.x.

Supplemental Content

Loading ...
Support Center